Duct tape occlusion treatment increased resolution in common paediatric warts

**QUESTION:** In patients with common paediatric warts, is duct tape occlusion treatment more effective than cryotherapy for improving wart resolution?

**Design**
Randomised (allocation concealed*), blinded (clinicians),* controlled trial with a follow up of ≤ 16 weeks.

**Setting**
Madigan Army Medical Center, Tacoma, Washington, USA.

**Patients**
61 patients (age range 3–22 y) who had common warts. Exclusion criteria included immunodeficiency states; chronic skin diseases (eg, eczema or psoriasis); allergy to adhesive tape; warts located on the face, periumgual, perianal, or genital areas; and previous cryotherapy for the same wart. Follow up was 84% (mean age 9 y, 51% girls).

**Intervention**
Patients were allocated to duct tape occlusion treatment for a maximum of 2 months or until resolution of the wart (n=50) or cryotherapy every 2–3 weeks for a maximum of 6 treatments or until resolution of the wart (n=31). Patients in the duct tape group received a supply of standard duct tape. The first piece of duct tape, cut as close to the size of the wart as possible, was applied to the wart in the clinic by nursing personnel and left in place for 6 days. After 6 days, the wart was debrided, and the tape left off over night and reapplied the next morning. Patients in the cryotherapy group received a standard application of liquid nitrogen to the wart for 10 seconds.

**Main outcome measures**
Complete resolution of the wart being studied.

**Main results**
More warts in the duct tape group than in the cryotherapy group had completely resolved at the end of the treatment period (table).

**Conclusion**
In patients with common paediatric warts, duct tape occlusion treatment was more effective than cryotherapy for improving wart resolution.

*See glossary.

**COMMENTARY**
Viral warts are common complaints. Although they are painful over a pressure point, the main reason for seeking treatment is cosmetic appearance. In addition to over the counter topical treatments, cryotherapy is available from physicians who widely believe that it is more effective. The trial by Focht et al and the systematic review by Gibbs et al raise a number of methodological issues that have been discussed elsewhere.1–2 Both studies call into question the effectiveness of freezing warts with liquid nitrogen. Should physicians abandon cryotherapy?

In the trial, duct tape was found to be more effective than cryotherapy, but the absolute effectiveness of cryotherapy was difficult to determine because no placebo group was used. In the systematic review, the average placebo cure rates were 30% in the 17 trials that used a placebo group. Surprisingly little is known about the longer term natural history of viral warts. A study by Massing and Epstein of 1000 institutionalised children suggested that over two thirds of participants (from primary or secondary care), as well as factors relating to the intervention such as timing, duration, and frequency of cryotherapy. Long term studies are needed to capture wart recurrences.1 Altman goes on to discuss design options for future RCTs, such as within patient comparisons and the importance of considering individual people and not warts as the unit of analysis.3

continued on next page
**Clinical cure?**

**Therapeutics EBM Volume 8 March/April 2003 59**

**5-fluorouracil group than in the placebo group in only 5-fluorouracil (3 RCTs): the cure rate was greater in the 5-fluorouracil group than in the placebo group (table). (5) Intral- esional interferons (6 RCTs): meta-analysis of 3 RCTs that compared interferon a with placebo showed that the groups did not differ for cure rate (table). (6) Dinitrochlorobenzene (DNCB) (2 RCTs): meta-analysis showed that the cure rate was greater in the DNCB group than in the placebo group (table). (7) Photodynamic treatment (PDT) (4 RCTs): 1 high quality RCT reported that the cure rate was greater in the aminole- vulinic PDT group than in the placebo PDT group (56% v 42% of warts, p < 0.05).

**Conclusions**

In healthy people with viral non-refractory warts, common topical applications containing salicylic acid and/or lactic acid are more effective than placebo for improving clinical cure. Evidence on the effectiveness of cryotherapy is inconclusive.

### Cure rates of different local treatments for cutaneous, non-genital warts in healthy people at 1–18 months*

<table>
<thead>
<tr>
<th>Comparisons</th>
<th>Number of RCTs (number of patients)</th>
<th>Weighted event rates</th>
<th>RBI (95% CI) NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T5FU v placebo</td>
<td>6 (376)</td>
<td>73% v 48%</td>
<td>62% (24 to 113)</td>
</tr>
<tr>
<td>ILS bleomycin v placebo</td>
<td>1 (31)</td>
<td>94% v 73%</td>
<td>28% (~8 to 78)</td>
</tr>
<tr>
<td>TDNCB v placebo</td>
<td>1 (128)</td>
<td>45% v 13%</td>
<td>263% (80 to 631)</td>
</tr>
<tr>
<td>Cryotherapy v placebo or no treatment</td>
<td>2 (60)</td>
<td>80% v 43%</td>
<td>83% (24 to 169)</td>
</tr>
<tr>
<td>ILS interferons v placebo</td>
<td>3 (150)</td>
<td>29% v 34%</td>
<td>12% (~195 to 74)</td>
</tr>
</tbody>
</table>

*ILS = Intralosional; RBI = relative benefit reduction; RCTs = randomised controlled trials; T5FU = topical 5-fluorouracil; TDNCB = topical dinitrochlorobenzene; TLA = topical lactic acid; TSA = topical salicylic acid. Other abbreviations defined in glossary; RBI, RBR, NNT, NNH and CI calculated from data in article using a random effects model.

### Data sources

Studies were identified by searching electronic databases that included Medline (1966 to May 2000), EMBASE/ Excerpta Medica (1980 to August 2000), and CINAHL (1982 to March 1999); hand searching 8 relevant journals; and by reviewing bibliographies of relevant articles. Experts in the field and pharmaceutical companies were contacted for unpublished studies.

### Study selection

Studies in any language were selected if they were randomised controlled trials (RCTs) of local treatments (all topical, intralesional, and surgical treatments, including cryotherapy but not systemic or psychological treat- ments) in people with clinically observed non-genital viral warts.

### Data extraction

Data were extracted on study setting, sample size, key components of the intervention, study quality and outcomes. The main outcome was clinical cure (defined as complete disappearance of elevated/warty skin) at the end of a treatment period.

### Main results

50 RCTs met the selection criteria. Meta-analyses were done using random effects models. (1) Simple topical agents containing salicylic acid and/or lactic acid for 6–12 weeks (13 RCTs): meta-analysis of 6 RCTs showed that the cure rate was higher in the treatment group than in the placebo group (table). (2) Cryotherapy (16 RCTs): meta-analysis of 2 RCTs that compared cryo- therapy with placebo showed that the groups did not differ for cure rate (table). (3) Intralesional bleomycin (4 RCTs): the only RCT that made the comparison (table). (5) Intral- esional interferons (6 RCTs): meta-analysis of 3 RCTs that compared interferon a with placebo showed that the groups did not differ for cure rate (table). (6) Dinitrochlorobenzene (DNCB) (2 RCTs): meta-analysis showed that the cure rate was greater in the DNCB group than in the placebo group (table). (7) Photodynamic treatment (PDT) (4 RCTs): 1 high quality RCT reported that the cure rate was greater in the aminole- vulinic PDT group than in the placebo PDT group (56% v 42% of warts, p < 0.05).

### Commentary—continued from previous page

In the meantime, as we await better evidence, when faced with someone presenting with a wart, it may be prudent to first consider doing nothing given the high rate of natural resolution of some warts. Then we should try out treatments that are best supported by the available evidence base and those with the least propensity to cause harm, such as topical salicylic acid gels or duct tape. Cryotherapy could be reserved as a third option should these 2 fail.

Professor Hywel C Williams

Centre of Evidence-Based Dermatology, Queen’s Medical Centre, Nottingham, England, UK

2 Altman DG Commentary: Systematic reviewers face challenges from various study designs. BMJ 2002;325:461